Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 3/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.43 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4840511 | 0.87 | L3MBTL1 (0.65) | L3MBTL1MAPTLMNASMN1; SMN2HTT | |
| SCHEMBL4833676 | 0.87 | L3MBTL1 (0.64) | L3MBTL1MAPTLMNASMN1; SMN2HTT | |
| SCHEMBL4843195 | 0.86 | L3MBTL1 (0.61) | L3MBTL1MAPTLMNASMN1; SMN2HTT | |
| SCHEMBL176858 | 0.84 | MAOB (0.59) | LMNASMN1; SMN2MAOBALDH1A1 | |
| SCHEMBL4841541 | 0.83 | L3MBTL1 (0.59) | L3MBTL1MAPTLMNASMN1; SMN2HTT | |
| SCHEMBL25229236 | 0.81 | LMNA (0.55) | L3MBTL1MAPTLMNASMN1; SMN2HTT | |
| SCHEMBL25660826 | 0.81 | LMNA (0.55) | L3MBTL1MAPTLMNASMN1; SMN2HTT | |
| SCHEMBL24627608 | 0.81 | L3MBTL1 (0.65) | L3MBTL1MAPTLMNASMN1; SMN2HTT | |
| SCHEMBL20758856 | 0.81 | L3MBTL1 (0.68) | L3MBTL1MAPTLMNASMN1; SMN2HTT | |
| SCHEMBL13267972 | 0.79 | L3MBTL1 (0.64) | L3MBTL1MAPTMAOBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465811-B2 | Indoline compounds | LABORATOIRES FOURNIER S.A. (FR) | 2008-12-16 | — | — | US | disclosed |
| US-20080119465-A1 | Novel Indoline Compounds | LABORATORIES FOURNIER S.A. (FR) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119465-A1 | Novel Indoline Compounds | GPR119, INSR, IRS1 | L3MBTL1 1493/4885MAPT 763/4885LMNA 1943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.